Search

Geron Corp

Open

SectorHealthcare

0.93 4.49

Overview

Share price change

24h

Current

Min

0.88

Max

0.92

Key metrics

By Trading Economics

Income

-13M

-17M

Sales

5.6M

57M

EPS

-0.02

Profit margin

-29.019

Employees

258

EBITDA

-16M

-12M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+347.43% upside

Dividends

By Acuity

Next Earnings

4 lis 2026

Market Stats

By TradingEconomics

Market Cap

-82M

739M

Previous open

-3.56

Previous close

0.93

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 paź 2026, 20:03 UTC

Geron Corporation shares fell sharply, continuing a three-day decline and reaching a notable low, remaining well below their 20-day moving average.

29 paź 2026, 20:07 UTC

News
Event

Wedbush maintains Outperform rating on Geron Corporation but lowers price target to $5; company discontinues Phase 3 IMpactMF trial for imetelstat.

28 paź 2026, 20:02 UTC

Social Media
Event
Macro Event
News

Geron Corporation's stock declined sharply after discontinuing its Phase 3 IMpactMF trial for imetelstat due to unlikely success in meeting primary survival endpoints.

27 paź 2026, 19:56 UTC

Geron Corporation is trading roughly flat, showing little change since Monday's close, and remains below its 20-day moving average.

26 paź 2026, 20:06 UTC

Geron Corp's shares advanced, building on previous gains.

23 paź 2026, 20:07 UTC

Geron Corp's shares are roughly flat, maintaining their position near Thursday's close amid broader market declines influenced by economic indicators and rising oil prices.

22 paź 2026, 23:46 UTC

In after-market trading, Geron Corp is advancing sharply, with a cumulative return of 3.57% since Thursday's close.

21 paź 2026, 23:41 UTC

Geron Corp shares advanced in after-market trading following Wednesday's close, briefly peaking before retracing slightly, but remain below their 20-day moving average.

20 paź 2026, 20:08 UTC

Geron Corp shares are trading higher, maintaining momentum amid a broader market trend with significant gains observed in regular trading hours.

19 paź 2026, 19:16 UTC

Geron Corp shares are advancing, reflecting broader market gains since Friday.

16 paź 2026, 23:06 UTC

Geron Corp shares advanced modestly higher in after-market trading on Friday.

15 paź 2026, 20:51 UTC

Geron Corp's shares advanced in after-market trading, rising notably from a low shortly after the close, reflecting stable performance within its one-month trading range.

14 paź 2026, 23:11 UTC

Geron Corp shares advanced in after-market trading, remaining modestly higher since Wednesday's close, despite earlier pulling back from a session high.

13 paź 2026, 20:01 UTC

Geron Corp shares are declining, remaining significantly below their 20-day moving average, with a cumulative return down since Monday's close.

12 paź 2026, 22:16 UTC

Geron Corp shares are trading lower in after-market hours, retracing from an earlier session peak and remaining below their 20-day moving average.

9 paź 2026, 19:45 UTC

Geron Corp shares are trading roughly flat, showing little change since Thursday's close and positioned below its 20-day moving average.

8 paź 2026, 23:10 UTC

Geron Corp's shares advanced in after-market trading, moving higher from a low to a high since Thursday's close.

6 paź 2026, 20:07 UTC

Geron Corp's shares fell sharply, reflecting broader market volatility, and remain significantly below their 20-day moving average amid a declining trend.

5 paź 2026, 20:06 UTC

Geron Corp's shares are advancing, recovering from earlier declines and trading higher throughout the morning, though settling near the lower end of their one-month range.

1 paź 2026, 20:07 UTC

Geron Corp shares fell sharply, continuing a downward trend and remaining below their 20-day moving average, near the lower end of their one-month range.

30 wrz 2026, 20:07 UTC

Geron Corp's shares are advancing, having closed higher since Tuesday, despite pulling back from an earlier session peak.

29 wrz 2026, 23:40 UTC

Geron Corp saw notable gains in after-market trading, reaching its highest point since Tuesday's close, though still below its 20-day moving average.

28 wrz 2026, 20:07 UTC

Geron Corp shares fell amid a broader market downturn, influenced by declines in major tech stocks and rising geopolitical tensions, reflecting increased volatility.

25 wrz 2026, 19:46 UTC

Geron Corp is trading higher, having peaked earlier before retracing, though it remains below its 20-day moving average amid broader market weakness.

24 wrz 2026, 20:07 UTC

Geron Corp is advancing during Thursday's trading session, having peaked in the mid-afternoon, although it remains below its 20-day moving average.

23 wrz 2026, 22:01 UTC

In after-market trading, Geron Corp has advanced notably, moving higher since Wednesday's close, despite being 11.49% below its 20-day moving average.

22 wrz 2026, 22:50 UTC

Geron Corp is advancing in after-market trading, recovering from earlier declines, though it remains below its 20-day moving average.

18 wrz 2026, 19:36 UTC

Geron Corp shares fell sharply, continuing a decline since Thursday and trading significantly below the 20-day moving average.

17 wrz 2026, 23:01 UTC

Geron Corp's shares rose in after-market trading, recovering from earlier losses to reach their highest level of the day since Thursday's close.

16 wrz 2026, 20:10 UTC

Geron Corp's shares fell sharply, continuing a decline from Tuesday and trading near the lower end of its one-month range.

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

347.43% upside

12 Months Forecast

Average 4 USD  347.43%

High 5 USD

Low 3 USD

Based on 4 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat